

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 9, 2021 (February 3, 2021)

APOLLO MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-37392
(Commission File
Number)

95-4472349
(I.R.S. Employer
Identification Number)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, CA 91801
(Address of principal executive offices) (zip code)

(626) 282-0288
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	AMEH	Nasdaq Capital Market

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 3, 2021, the board of directors of Apollo Medical Holdings, Inc. (the “Company”) appointed Brandon Sim as the Company’s Chief Operating Officer, effective February 3, 2021. In addition to his new position, Mr. Sim will remain as the Company’s Chief Technology Officer and Vice President of Engineering.

Brandon Sim, 27, joined the Company as a Project Manager in June 2019. He was promoted to Interim Chief Technology Officer in September 2019 and named Chief Technology Officer and Vice President of Engineering in February 2020. In May 2020, he and Eric Chin were named Interim Co-Chief Operating Officers. Prior to joining the Company, he served as Quantitative Researcher at Citadel Securities since 2015. From 2012 to 2014, Mr. Sim served as Chief Technology Officer at Theratech, a medical device company focused on developing a low-cost, simple-to-use patch for automated drug delivery. Mr. Sim received his Master of Science in Computer Science and Engineering and Bachelor of Arts in Statistics and Physics, Magna Cum Laude with High Honors, from Harvard University. Mr. Sim is the son of Dr. Kenneth Sim, the Company’s Executive Chairman and Co-Chief Executive Officer.

In connection with Brandon Sim’s appointment as the Company’s Chief Operating Officer, his annual base salary has been increased by \$275,000 to \$375,000. He will remain eligible for an annual bonus, equity awards and other employee benefits in accordance with the Company’s executive compensation program.

As a result of Mr. Sim’s promotion, Eric Chin is no longer Interim Co-Chief Operating Officer of the Company. However, Mr. Chin will remain as the Company’s Chief Financial Officer and Secretary.

A copy of the press release regarding Brandon Sim’s appointment is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description
99.1	Apollo Medical Holdings, Inc. press release issued on February 9, 2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

APOLLO MEDICAL HOLDINGS, INC.

Dated: February 9, 2021

By: /s/ Thomas S. Lam, M.D., M.P.H.
Name: Thomas S. Lam, M.D., M.P.H.
Title: Co-Chief Executive Officer and President



Apollo Medical Holdings, Inc. Promotes Chief Technology Officer Brandon Sim to Chief Operating Officer

ALHAMBRA, Calif., February 9, 2021 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare management company, today announced it has appointed Chief Technology Officer Brandon Sim to the role of Chief Operating Officer (COO), effective February 3, 2021.

In his role as Chief Operating Officer, Mr. Sim will assume responsibility for the Company's overall strategy, end-to-end service delivery and all non-clinical operations. Mr. Sim will also continue to lead all technology aspects of ApolloMed's business, including software engineering, information technology, data management and electronic data interchange functions.

Thomas S. Lam, M.D., M.P.H., Co-Chief Executive Officer and President of ApolloMed, stated, "Elevating Brandon to the COO role strengthens our management team as his established leadership and focus on technological innovation at ApolloMed will continue to strengthen our position as one of the most significant physician-centric, risk-bearing healthcare management companies in the country. Since joining ApolloMed in 2019, Brandon has not only brought a laser focus on operational excellence but has also built our engineering team and technology platform from the ground up. As a result of his efforts, the Company and our contracted physicians have benefited from increased operational efficiencies and improved outcomes for our patients. I am confident that Brandon's expanded role on our leadership team will help the Company continue to innovate in this ever-changing industry and continue to execute on our exciting growth strategy."

Mr. Sim added, "I am incredibly excited by this opportunity to help lead the Company towards further innovation in the industry and to continue building upon our track record of operational excellence and profitable growth. Our goal is to leverage our expertise in healthcare, operations, and technology to scale our successful population health management model nationwide. I am energized to continue working on healthcare's most costly and difficult challenges in order to ensure the delivery of high-quality care to our patients in a cost-effective manner."

Mr. Sim has served as ApolloMed's Chief Technology Officer and Vice President of Engineering since 2019 and was appointed ApolloMed's Interim Co-Chief Operating Officer in May 2020. He previously served as Quantitative Researcher at Citadel Securities from 2015 to 2019. From 2012 to 2014, Mr. Sim served as Chief Technology Officer at Theratech, a medical device company focused on developing a low-cost, simple-to-use patch for automated drug delivery. Mr. Sim received his Master of Science in Computer Science and Engineering and Bachelor of Arts in Statistics and Physics, Magna Cum Laude with High Honors, from Harvard University.

About Apollo Medical Holdings, Inc.

ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an

integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner.

Headquartered in Alhambra, California, ApolloMed's subsidiaries include management services organizations ("MSOs"), affiliated independent practice associations ("IPAs") and a Next Generation Accountable Care Organization ("NGACO"). Network Medical Management, Inc. and Apollo Medical Management, Inc. are the administrative and managerial services companies for the affiliated physician owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the Allied Pacific of California IPA, Alpha Care Medical Group, Inc. and Accountable Health Care IPA brands. These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation. Our NGACO operates under the APA ACO, Inc. brand and participates in the Centers for Medicare & Medicaid Services program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program's attribution-based risk sharing model. For more information, please visit www.apollomed.net.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations
(626) 943-6491
investors@apollomed.net

Carolyne Sohn, The Equity Group
(415) 568-2255
csohn@equityny.com